IN2014DN07799A - - Google Patents

Info

Publication number
IN2014DN07799A
IN2014DN07799A IN7799DEN2014A IN2014DN07799A IN 2014DN07799 A IN2014DN07799 A IN 2014DN07799A IN 7799DEN2014 A IN7799DEN2014 A IN 7799DEN2014A IN 2014DN07799 A IN2014DN07799 A IN 2014DN07799A
Authority
IN
India
Prior art keywords
antibody
present disclosure
rob04
angiogenesis
pharmaceutical composition
Prior art date
Application number
Other languages
English (en)
Inventor
Yoshitaka Isumi
Toshiyuki Sato
Jun Hasegawa
Tatsuya Inoue
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2012103929A external-priority patent/JP2013230115A/ja
Priority claimed from JP2013011042A external-priority patent/JP2014141434A/ja
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of IN2014DN07799A publication Critical patent/IN2014DN07799A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
IN7799DEN2014 2012-04-27 2013-04-26 IN2014DN07799A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012103929A JP2013230115A (ja) 2012-04-27 2012-04-27 抗ｒｏｂｏ４抗体
JP2013011042A JP2014141434A (ja) 2013-01-24 2013-01-24 抗ｒｏｂｏ４抗体
PCT/IB2013/053312 WO2013160879A1 (fr) 2012-04-27 2013-04-26 Anticorps anti-robo4

Publications (1)

Publication Number Publication Date
IN2014DN07799A true IN2014DN07799A (fr) 2015-05-15

Family

ID=48670623

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7799DEN2014 IN2014DN07799A (fr) 2012-04-27 2013-04-26

Country Status (22)

Country Link
US (2) US9683040B2 (fr)
EP (1) EP2841457B1 (fr)
JP (2) JP5897205B2 (fr)
KR (2) KR101950898B1 (fr)
CN (1) CN104768973B (fr)
AU (1) AU2013254313B2 (fr)
BR (1) BR112014026649A2 (fr)
CA (1) CA2868074A1 (fr)
CO (1) CO7111295A2 (fr)
DK (1) DK2841457T3 (fr)
ES (1) ES2733434T3 (fr)
IN (1) IN2014DN07799A (fr)
MX (1) MX356749B (fr)
MY (1) MY166821A (fr)
NZ (1) NZ629291A (fr)
PH (1) PH12014502382B1 (fr)
PL (1) PL2841457T3 (fr)
RU (1) RU2682451C2 (fr)
SG (1) SG11201405718QA (fr)
TW (1) TWI606065B (fr)
WO (1) WO2013160879A1 (fr)
ZA (1) ZA201406235B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN07799A (fr) * 2012-04-27 2015-05-15 Daiichi Sankyo Co Ltd
CN110922481A (zh) 2015-09-24 2020-03-27 第一三共株式会社 抗garp抗体
WO2018070390A1 (fr) 2016-10-12 2018-04-19 第一三共株式会社 Composition contenant un anticorps anti-robo4 et un autre agent
KR20210070643A (ko) 2019-12-05 2021-06-15 김명배 자체 발전 웨어러블 다리
US20250066471A1 (en) 2022-02-16 2025-02-27 Institut National de la Santé et de la Recherche Médicale Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer
WO2025045139A1 (fr) * 2023-08-31 2025-03-06 舒泰神（北京）生物制药股份有限公司 Anticorps reconnaissant de manière spécifique robo2 et son utilisation
CN117384290B (zh) * 2023-12-11 2024-04-09 苏州因特药物研发有限公司 人源robo1结合分子及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0656941B1 (fr) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Procedes de production d'elements de paires de liaison specifiques
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2177367A1 (fr) 1993-12-03 1995-06-08 Andrew David Griffiths Proteines et peptides de liaison recombines
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
EP2275540B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
ATE360068T1 (de) * 2000-11-06 2007-05-15 Cancer Rec Tech Ltd Bildgebende verfahren, diagnose und behandlung von krankheiten
JP4583638B2 (ja) 2001-03-15 2010-11-17 独立行政法人科学技術振興機構 アセチルリジン認識モノクローナル抗体及びその製造方法
WO2004003163A2 (fr) 2002-06-27 2004-01-08 University Of Utah Research Foundation Procedes et compositions de manipulation de navigation guidee de tubes endotheliaux pendant une angiogenese
US20060099143A1 (en) 2002-11-20 2006-05-11 Roy Bicknell Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis
EA013225B1 (ru) 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
JP2010512327A (ja) 2006-12-11 2010-04-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 病的血管形成および脈管透過性の処置用の組成物および方法
US7834154B2 (en) * 2007-02-09 2010-11-16 Genentech, Inc. Anti-ROBO4 antibodies and uses therefor
TWI480050B (zh) * 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
IN2014DN07799A (fr) * 2012-04-27 2015-05-15 Daiichi Sankyo Co Ltd

Also Published As

Publication number Publication date
ZA201406235B (en) 2016-07-27
BR112014026649A2 (pt) 2017-07-18
PL2841457T3 (pl) 2019-09-30
PH12014502382A1 (en) 2015-01-12
MY166821A (en) 2018-07-23
NZ629291A (en) 2016-09-30
AU2013254313A1 (en) 2014-09-18
JP2016175893A (ja) 2016-10-06
KR101950898B1 (ko) 2019-02-22
CN104768973A (zh) 2015-07-08
JP2015515490A (ja) 2015-05-28
CN104768973B (zh) 2019-01-22
SG11201405718QA (en) 2014-10-30
JP6267733B2 (ja) 2018-01-24
CO7111295A2 (es) 2014-11-10
WO2013160879A1 (fr) 2013-10-31
ES2733434T3 (es) 2019-11-29
US20150098945A1 (en) 2015-04-09
HK1207093A1 (en) 2016-01-22
JP5897205B2 (ja) 2016-03-30
DK2841457T3 (da) 2019-07-22
EP2841457A1 (fr) 2015-03-04
TWI606065B (zh) 2017-11-21
MX356749B (es) 2018-06-12
RU2014147616A (ru) 2016-06-20
MX2014012351A (es) 2015-01-12
EP2841457B1 (fr) 2019-04-24
PH12014502382B1 (en) 2015-01-12
US9683040B2 (en) 2017-06-20
RU2682451C2 (ru) 2019-03-19
KR20150008074A (ko) 2015-01-21
CA2868074A1 (fr) 2013-10-31
US20160108120A1 (en) 2016-04-21
AU2013254313B2 (en) 2017-03-30
US9562096B2 (en) 2017-02-07
TW201348257A (zh) 2013-12-01
KR20190020838A (ko) 2019-03-04

Similar Documents

Publication Publication Date Title
PH12014502382A1 (en) Anti-robo4-antibody
HUE049171T2 (hu) Rák diagnózisban felhasználható Claudin 18.2 elleni antitestek
EP2761554A4 (fr) Paiements sociaux de proximité
EP2786664A4 (fr) Procédé de préparation de pulpe pour cigarette électronique et narguilé classique
EP2863910A4 (fr) Compositions et procédés pour réguler l'homéostasie du glucose et l'action de l'insuline
IL233796A0 (en) Correlating brain signal to intentional and unintentionall changes in brain state
PL2935595T3 (pl) Sposób i urządzenie do wytwarzania biogazu z biomasy zawierającej lignocelulozę
EP2668281A4 (fr) Compositions et méthodes pour la production de succinate
EP3030244A4 (fr) Polyconjugués pour l'administration de déclencheurs d'arni à des cellules tumorales in vivo
EP2917235A4 (fr) Compositions d'anticorps et procédés d'immunodosage pour détecter des isoformes de l'hormone antimüllérienne
EP2832694A4 (fr) Cristal germe de zéolite ddr, procédé pour le produire, et procédé pour produire un film de zéolite ddr
IL236197A0 (en) In vitro method for the diagnosis and surveillance of cancer
WO2014209905A3 (fr) Méthodes et compositions destinées à détecter et à diagnostiquer des maladies et des affections
EP2742400A4 (fr) Suspension et/ou ralentissement de processus pour une veille connectée
MX2014004211A (es) Composiciones de recubrimiento para moldes y machos de fundicion inorganicos que comprenden esteres de acido formico y uso de los mismos.
EP2771688A4 (fr) Anticorps anti-psa libres en tant que produits de diagnostic, de pronostic et thérapeutiques pour le cancer de la prostate
EP3031914A4 (fr) AMADORIASE MODIFIÉE ET SON PROCÉDÉ DE PRODUCTION, AGENT PERMETTANT D'AMÉLIORER LA RÉSISTANCE AUX TENSIOACTIFS DE L'AMADORIASE ET COMPOSITION PERMETTANT DE MESURER L'HbA1c À L'AIDE DE CELLE-CI
IN2014MN02114A (fr)
AU343147S (en) Easel
EP3009008A4 (fr) Céréale contenant hericium erinaceum et procédé pour la produire
EP2714923A4 (fr) Méthodes et compositions pour la détection de toxines de clostridium difficile fonctionnelles
PL2836602T3 (pl) Sposoby i układy do sacharyfikacji biomasy
EP3049142A4 (fr) Extension pour cathéter et ses procédés de production et d'utilisation
EP3025282A4 (fr) Système et procédé d'extraction d'attributs de changement matériel à partir de signaux de données conservés et analysés au fil du temps afin de prévoir des changements futurs dans des prédicteurs traditionnels
EP2918678A4 (fr) Anticorps anti-adam28 pour traiter le cancer